Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Berlin Cures Achieves Milestone in BC 007 Phase II Trial for Long COVID
Details : BC 007 (rovunaptabin) is a novel therapeutic candidate using DNA-based aptamers to target and neutralize functional autoantibodies against G-protein coupled receptors for Long COVID.
Product Name : BC 007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Berlin Cures' BC 007 Targets Long COVID with Over 50% Patient Recruitment
Details : BC 007 is a DNA-based aptamer designed to specifically target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors. It is being evaluated for Long Covid.
Product Name : BC 007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19
Details : Berlin Cures Holding AG is evaluating BC 007, a β1-adrenoceptor autoantibody neutralizing ssDNA product, for the treatment of COVID-19. BC 007 consists of a synthetically produced short and unmodified aptamer, which is able to bind to the spike protein ...
Product Name : BC 007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable